Bruton's tyrosine kinase inhibitor for multiple sclerosis: new hope or false dawn.

Robertson, Neil P. ORCID: https://orcid.org/0000-0002-5409-4909 2025. Bruton's tyrosine kinase inhibitor for multiple sclerosis: new hope or false dawn. Journal of Neurology 272 (1) , 106. 10.1007/s00415-025-12892-w Item availability restricted.

PDF - Accepted Post-Print Version Restricted to Repository staff only until 11 January 2026 due to copyright restrictions. Download (152kB)

Abstract

The first of several phase 3 trials examining efficacy in relapsing MS has not been able to demonstrate a significant benefit and has also raised important safety concerns. More results are on their way and it will be important to understand whether the safety signals identified are drug- or class-specific and whether other BTKi also fail to reach their endpoints for relapsing MS. However, as reported in preliminary data for another BTKi, it may be that they will have more of a role in progressive disease as hinted by the unraveling of relevant molecular mechanisms and pathways. [Abstract copyright: © 2025. Springer-Verlag GmbH Germany, part of Springer Nature.]

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Medicine
Publisher:	Springer
ISSN:	0340-5354
Date of First Compliant Deposit:	5 February 2025
Date of Acceptance:	16 December 2024
Last Modified:	05 Feb 2025 11:45
URI:	https://orca.cardiff.ac.uk/id/eprint/175561

Actions (repository staff only)

Edit Item